Szilvia Mosolits

Summary

Affiliation: Karolinska Institute
Country: Sweden

Publications

  1. ncbi request reprint Towards therapeutic vaccines for colorectal carcinoma: a review of clinical trials
    Szilvia Mosolits
    Department of Oncology, Cancer Center Karolinska, Karolinska University Hospital, S 171 76 Stockholm, Sweden
    Expert Rev Vaccines 4:329-50. 2005
  2. ncbi request reprint Durable carcinoembryonic antigen (CEA)-specific humoral and cellular immune responses in colorectal carcinoma patients vaccinated with recombinant CEA and granulocyte/macrophage colony-stimulating factor
    Gustav J Ullenhag
    Department of Oncology, Radiology and Clinical Immunology, Section of Oncology, Uppsala University Hospital, Uppsala, Sweden
    Clin Cancer Res 10:3273-81. 2004
  3. ncbi request reprint Clinical results of vaccine therapy for cancer: learning from history for improving the future
    Aniruddha Choudhury
    Department of Oncology, Cancer Centre Karolinska, Karolinska University, Hospital Solna, SE 171 76 Stockholm, Sweden
    Adv Cancer Res 95:147-202. 2006
  4. ncbi request reprint Targeting human Ep-CAM in transgenic mice by anti-idiotype and antigen based vaccines
    Szilvia Mosolits
    Immune and Gene Therapy Laboratory, Department of Oncology, Radiumhemmet, Karolinska Institute, Stockholm, Sweden
    Int J Cancer 112:669-77. 2004
  5. ncbi request reprint Immunization of colorectal carcinoma patients with a recombinant canarypox virus expressing the tumor antigen Ep-CAM/KSA (ALVAC-KSA) and granulocyte macrophage colony- stimulating factor induced a tumor-specific cellular immune response
    Gustav J Ullenhag
    Department of Oncology, Radiology and Clinical Immunology, Section of Oncology, Uppsala University Hospital, SE 751 85 Uppsala, Sweden
    Clin Cancer Res 9:2447-56. 2003
  6. ncbi request reprint Immunogenic regions of the GA733-2 tumour-associated antigen recognised by autoantibodies of patients with colorectal carcinoma
    Szilvia Mosolits
    Immune and Gene Therapy Laboratory, Cancer Centre Karolinska, Karolinska Hospital, 171 76 Stockholm, Sweden
    Cancer Immunol Immunother 51:209-18. 2002
  7. ncbi request reprint Vaccination with Ep-CAM protein or anti-idiotypic antibody induces Th1-biased response against MHC class I- and II-restricted Ep-CAM epitopes in colorectal carcinoma patients
    Szilvia Mosolits
    Immune and Gene Therapy Laboratory, Department of Oncology Radiumhemmet, Karolinska Institute, Stockholm, Sweden
    Clin Cancer Res 10:5391-402. 2004
  8. ncbi request reprint T-cell receptor BV gene usage in colorectal carcinoma patients immunised with recombinant Ep-CAM protein or anti-idiotypic antibody
    Szilvia Mosolits
    Immune and Gene Therapy Laboratory, Department of Oncology Radiumhemmet, Karolinska Institute, Stockholm, Sweden
    Cancer Immunol Immunother 54:557-70. 2005

Collaborators

  • Philippe Moingeon
  • Hakan Mellstedt
  • Eva D Rossmann
  • Gustav J Ullenhag
  • Aniruddha Choudhury
  • Jan Erik Frödin
  • Parviz Kokhaei
  • Lotta Hansson
  • Marzia Palma
  • Mahmood Jeddi-Tehrani
  • Bo Nilsson
  • Ali Samanci
  • Emma Eriksson
  • Karin Strigård
  • Moustapha Hassan
  • Shahryar Kiaii
  • Marie Claude Bonnet
  • Hodjattallah Rabbani

Detail Information

Publications8

  1. ncbi request reprint Towards therapeutic vaccines for colorectal carcinoma: a review of clinical trials
    Szilvia Mosolits
    Department of Oncology, Cancer Center Karolinska, Karolinska University Hospital, S 171 76 Stockholm, Sweden
    Expert Rev Vaccines 4:329-50. 2005
    ..Randomized controlled vaccine trials targeting molecularly defined tumor antigens are warranted, particularly in colon carcinoma with minimal residual disease...
  2. ncbi request reprint Durable carcinoembryonic antigen (CEA)-specific humoral and cellular immune responses in colorectal carcinoma patients vaccinated with recombinant CEA and granulocyte/macrophage colony-stimulating factor
    Gustav J Ullenhag
    Department of Oncology, Radiology and Clinical Immunology, Section of Oncology, Uppsala University Hospital, Uppsala, Sweden
    Clin Cancer Res 10:3273-81. 2004
    ..The aim of the present study was to analyze the immunological and clinical effects of vaccination with CEA together with the adjuvant granulocyte/macrophage colony-stimulating factor (GM-CSF)...
  3. ncbi request reprint Clinical results of vaccine therapy for cancer: learning from history for improving the future
    Aniruddha Choudhury
    Department of Oncology, Cancer Centre Karolinska, Karolinska University, Hospital Solna, SE 171 76 Stockholm, Sweden
    Adv Cancer Res 95:147-202. 2006
    ....
  4. ncbi request reprint Targeting human Ep-CAM in transgenic mice by anti-idiotype and antigen based vaccines
    Szilvia Mosolits
    Immune and Gene Therapy Laboratory, Department of Oncology, Radiumhemmet, Karolinska Institute, Stockholm, Sweden
    Int J Cancer 112:669-77. 2004
    ..The results might have implications for the design of future vaccine trials using Ep-CAM as a target structure...
  5. ncbi request reprint Immunization of colorectal carcinoma patients with a recombinant canarypox virus expressing the tumor antigen Ep-CAM/KSA (ALVAC-KSA) and granulocyte macrophage colony- stimulating factor induced a tumor-specific cellular immune response
    Gustav J Ullenhag
    Department of Oncology, Radiology and Clinical Immunology, Section of Oncology, Uppsala University Hospital, SE 751 85 Uppsala, Sweden
    Clin Cancer Res 9:2447-56. 2003
    ..Expression of the tumor antigen in a viral vector may facilitate appropriate antigen presentation. The feasibility of an Ep-CAM/KSA-specific therapeutic vaccination was investigated in cancer patients...
  6. ncbi request reprint Immunogenic regions of the GA733-2 tumour-associated antigen recognised by autoantibodies of patients with colorectal carcinoma
    Szilvia Mosolits
    Immune and Gene Therapy Laboratory, Cancer Centre Karolinska, Karolinska Hospital, 171 76 Stockholm, Sweden
    Cancer Immunol Immunother 51:209-18. 2002
    ..No significant correlation was found between the presence of anti-peptide antibodies in CRC patients and clinical stage or overall survival. The results provide additional evidence for immune recognition of CRC by the host...
  7. ncbi request reprint Vaccination with Ep-CAM protein or anti-idiotypic antibody induces Th1-biased response against MHC class I- and II-restricted Ep-CAM epitopes in colorectal carcinoma patients
    Szilvia Mosolits
    Immune and Gene Therapy Laboratory, Department of Oncology Radiumhemmet, Karolinska Institute, Stockholm, Sweden
    Clin Cancer Res 10:5391-402. 2004
    ..The aim of the present study was to evaluate and compare the safety and immunogenicity of a recombinant Ep-CAM protein and a human anti-idiotypic antibody (anti-Id) mimicking Ep-CAM...
  8. ncbi request reprint T-cell receptor BV gene usage in colorectal carcinoma patients immunised with recombinant Ep-CAM protein or anti-idiotypic antibody
    Szilvia Mosolits
    Immune and Gene Therapy Laboratory, Department of Oncology Radiumhemmet, Karolinska Institute, Stockholm, Sweden
    Cancer Immunol Immunother 54:557-70. 2005
    ....